Home|DSIJArticleDetail

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high
Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

The shares of the company saw a spurt in volume by more than 2 times.

Kiran Shroff Article rating: 5.0

The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.

Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why
Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why

Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why

The company has a market cap of over Rs 17,000 crore with a PE of 55x, an ROE of 27 per cent and an ROCE of 33 per cent.

Kiran Shroff Article rating: 4.5

The stock gave multibagger returns of 250 per cent in 1 year, 720 per cent in 3 years and a whopping 2,700 per cent in 5 years.

Mukul Agrawal and Vijay Kedia Gains Rs 6.71 Crore and Rs 19.19 Crore as Stock Hits Upper Circuit Today: Stock Rallies Over 900 Per cent in Just 2 Years!
Mukul Agrawal and Vijay Kedia Gains Rs 6.71 Crore and Rs 19.19 Crore as Stock Hits Upper Circuit Today: Stock Rallies Over 900 Per cent in Just 2 Years!

Mukul Agrawal and Vijay Kedia Gains Rs 6.71 Crore and Rs 19.19 Crore as Stock Hits Upper Circuit Today: Stock Rallies Over 900 Per cent in Just 2 Years!

The company’s shares have delivered a multibagger return of over 200 per cent in the past 1 year.

Rakesh Deshmukh Article rating: 5.0

The company’s shares have delivered a multibagger return of over 200 per cent in the past 1 year.

DSIJ MINDSHARE

Mkt Commentary21-Nov, 2024

Multibaggers21-Nov, 2024

Mindshare21-Nov, 2024

Mindshare21-Nov, 2024

Mindshare21-Nov, 2024

Knowledge

MF15-Nov, 2024

General15-Nov, 2024

MF14-Nov, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList